ITC0014
ITC0014
ITC0014
from
$507.00
Price in reward points: 507
- Catalog: ITC0014
- Gene/Protein: CASP9
- Product Description: Immunotag™ Cleaved-Caspase-9 p35 (D315) Polyclonal Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein Caspase-9 p35 (D315) Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC-p,IF,ELISA Recommended Dilution WB 1:500-2000, IHC-p 1:50-300, IF 1:50-300 Concentration 1 mg/ml Reactive Species Human Host Species Rabbit Immunogen The antiserum was produced against synthesized peptide derived from human Caspase 9. AA range:266-315 Specificity Cleaved-Caspase-9 p35 (D315) Polyclonal Antibody detects endogenous levels of fragment of activated Caspase-9 p35 protein resulting from cleavage adjacent to D315. Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen Form Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Gene Name CASP9 Accession No. P55211 Alternate Names CASP9; MCH6; Caspase-9; CASP-9; Apoptotic protease Mch-6; Apoptotic protease-activating factor 3; APAF-3; ICE-like apoptotic protease 6; ICE-LAP6 Description caspase 9(CASP9) Homo sapiens This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein can undergo autoproteolytic processing and activation by the apoptosome, a protein complex of cytochrome c and the apoptotic peptidase activating factor 1; this step is thought to be one of the earliest in the caspase activation cascade. This protein is thought to play a central role in apoptosis and to be a tumor suppressor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013], Cell Pathway/ Category p53,Apoptosis_Inhibition,Apoptosis_Mitochondrial,Apoptosis_Overview,VEGF,Alzheimer's disease,Parkinson's disease,Amyotrophic lateral sclerosis (ALS),Huntington's disease,Pathways in cancer,Colorectal cancer,Pancreatic cancer,Endometrial cancer,Prostate cancer,Small cell lung cancer,Non-small cell lung cancer,Viral myocarditis, Protein Expression Brain,Eye,Liver,Lymph,Stomach cancer,T-cell, Subcellular Localization nucleus,mitochondrion,cytosol,apoptosome, Protein Function catalytic activity:Strict requirement for an Asp residue at position P1 and with a marked preference for His at position P2. It has a preferred cleavage sequence of Leu-Gly-His-Asp-|-Xaa.,function:Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP).,function:Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9.,online information:Caspase-9 entry,PTM:Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events.,similarity:Belongs to the peptidase C14A family.,similarity:Contains 1 CARD domain.,subunit:Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10) subunit. Caspase-9 and APAF1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome C and ATP. Interacts with the inhibitors BIRC2, BIRC4, BIRC5 and BIRC7.,tissue specificity:Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues., Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet | |
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | Caspase-9 p35 (D315) |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC-p,IF,ELISA |
| Recommended Dilution | WB 1:500-2000, IHC-p 1:50-300, IF 1:50-300 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Caspase 9. AA range:266-315 |
| Specificity | Cleaved-Caspase-9 p35 (D315) Polyclonal Antibody detects endogenous levels of fragment of activated Caspase-9 p35 protein resulting from cleavage adjacent to D315. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Gene Name | CASP9 |
| Accession No. | P55211 |
| Alternate Names | CASP9; MCH6; Caspase-9; CASP-9; Apoptotic protease Mch-6; Apoptotic protease-activating factor 3; APAF-3; ICE-like apoptotic protease 6; ICE-LAP6 |
| Description | caspase 9(CASP9) Homo sapiens This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein can undergo autoproteolytic processing and activation by the apoptosome, a protein complex of cytochrome c and the apoptotic peptidase activating factor 1; this step is thought to be one of the earliest in the caspase activation cascade. This protein is thought to play a central role in apoptosis and to be a tumor suppressor. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013], |
| Cell Pathway/ Category | p53,Apoptosis_Inhibition,Apoptosis_Mitochondrial,Apoptosis_Overview,VEGF,Alzheimer's disease,Parkinson's disease,Amyotrophic lateral sclerosis (ALS),Huntington's disease,Pathways in cancer,Colorectal cancer,Pancreatic cancer,Endometrial cancer,Prostate cancer,Small cell lung cancer,Non-small cell lung cancer,Viral myocarditis, |
| Protein Expression | Brain,Eye,Liver,Lymph,Stomach cancer,T-cell, |
| Subcellular Localization | nucleus,mitochondrion,cytosol,apoptosome, |
| Protein Function | catalytic activity:Strict requirement for an Asp residue at position P1 and with a marked preference for His at position P2. It has a preferred cleavage sequence of Leu-Gly-His-Asp-|-Xaa.,function:Involved in the activation cascade of caspases responsible for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to activation of the protease which then cleaves and activates caspase-3. Proteolytically cleaves poly(ADP-ribose) polymerase (PARP).,function:Isoform 2 lacks activity is an dominant-negative inhibitor of caspase-9.,online information:Caspase-9 entry,PTM:Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3 generate the two active subunits. Caspase-8 and -10 can also be involved in these processing events.,similarity:Belongs to the peptidase C14A family.,similarity:Contains 1 CARD domain.,subunit:Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10) subunit. Caspase-9 and APAF1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome C and ATP. Interacts with the inhibitors BIRC2, BIRC4, BIRC5 and BIRC7.,tissue specificity:Ubiquitous, with highest expression in the heart, moderate expression in liver, skeletal muscle, and pancreas. Low levels in all other tissues., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |